Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Date:3/11/2008

pulation.

Other Preclinical Programs:

-- Preclinical data presented at the 5th Annual International

Anti-Angiogenesis Conference confirmed that Peregrine's fully human,

selective anti-VEGF antibody R84 was as effective as Avastin(R) in

inhibiting tumor growth in a model of human breast cancer. Selective

anti-VEGF agents may have potential advantages over non-selective

approaches.

Avid Bioservices:

-- Wholly owned manufacturing subsidiary Avid Bioservices signed an

agreement with ARIUS Research to produce clinical supplies of their

lead cancer stem cell anti-CD44 antibody.

-- Avid continued to demonstrate strong revenue performance during the

third quarter of fiscal year 2008.

Conference Call

The company will host a conference call today, March 11, 2008 at 11:30 a.m. EDT/8:30 a.m. PDT to discuss its third quarter FY 2008 financial results.

To listen to a live broadcast of the call over the Internet or to review the archived call, please visit: http://www.peregrineinc.com. The webcast will be archived on Peregrine's website for approximately 30 days.

To listen to the conference call via telephone, please call the following number approximately 10 minutes prior to the scheduled start time and request to join the Peregrine Pharmaceuticals call: 1 (800) 860-2442. A telephonic replay of the conference call will be available starting approximately one hour after the conclusion of the call through March 18, 2008 by calling (877) 344-7529, passcode 382933#.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infec
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
2. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
3. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
4. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
5. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
6. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
7. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
8. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
9. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
10. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
11. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 Tris Pharma, a ... technologies, today announced that it has been selected as ... Industry Association,s 2014 Awards for Excellence competition ... an independent panel of judges from SCORE (Counselors to ... winners will be honored at a gala event to ...
(Date:8/27/2014)... BIOEQUA, an innovative line of skin care ... handheld spray, has made its EQUA ESSENTIAL line available ... brand began with an unexpected discovery in an emergency ... that the application of nanospray technology allowed for liquid ... to skin's basal layer. This resulted in immediate absorption ...
(Date:8/27/2014)... White City, OR (PRWEB) August 27, 2014 ... Supply Report, “Consolidation continues to reshape the look and ... in nutrition. Consumer demand for higher-quality ingredients will push ... the North American market have experienced strong market growth ... and ethical attributes in their food and cosmetics to ...
(Date:8/27/2014)... WriteResult, LLC – a premier provider of ... superiority when it comes to meeting the needs of ... of their most recent study closeout on-time and with ... digital writing platform to collect Patient Reported Outcomes electronically ... drew data from a number of assessments including the ...
Breaking Biology Technology:Tris Pharma Selected as an award winner in the New Jersey Business & Industry Association's 2014 Awards for Excellence 2BIOEQUA'S EQUA ESSENTIAL Product Line Redefines Skin Care & Now Available in America 2Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 2Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 3A Perfect Record: WriteResult Maintains a 100% On-Time ePRO Record with Latest Irritable Bowel (IBS) Study Data Lock 2
... Ala., Jan. 8 BioCryst Pharmaceuticals, Inc. (Nasdaq: ... Chief Executive Officer and Dr. William P. Sheridan, Chief Medical ... J.P. Morgan 27th Annual Healthcare Conference on Thursday, January 15, ... be held January 12-15, 2009 in San Francisco.A link to ...
... DNDN ) today announced that management will present ... Francisco on Thursday, January 15, 2009 at 11:00 a.m. PT. ... be accessible through the Investor Relations section of the Dendreon ... to the live webcast, it will be archived on the ...
... Medical, Inc., the global leader in devices for clot ... has completed a $15 million round of financing. ... New Enterprise Associates, Inc. (NEA) and includes other existing ... the last several months made the opportunity to participate ...
Cached Biology Technology:BioCryst to Present at the J.P. Morgan 27th Annual Healthcare Conference 2BioCryst to Present at the J.P. Morgan 27th Annual Healthcare Conference 3Concentric Medical Closes on $15 Million Financing 2
(Date:8/27/2014)... NY (June, 2014) Outstanding basic research, a ... a dedication to patient care have earned the ... University Medical Center (CUMC) and NewYork-Presbyterian Hospital an ... the National Cancer Institute (NCI). The grant renews ... NCI-designated Comprehensive Cancer Centers in New York City ...
(Date:8/27/2014)... growing number of studies have shown that ... pathogenesis of Parkinson,s disease. Previous studies from ... University in China have shown that baicalin ... reduced divalent metal transporter 1 expression, and ... nigra of rotenone-induced Parkinson,s disease rats. However, ...
(Date:8/27/2014)... the Happy Camp Complex of fires had consumed 24,939 ... had consumed 35,530 as of eight hours ago. ... Camp Ranger District of the Klamath National Forest when ... 2014. All but three of those fires are now ... contained fires and their size at containment: Delta, 150 ...
Breaking Biology News(10 mins):Herbert Irving Comprehensive Cancer Center awarded $18 million grant 2Herbert Irving Comprehensive Cancer Center awarded $18 million grant 3Herbert Irving Comprehensive Cancer Center awarded $18 million grant 4Happy Camp and July Fire Complexes in California 2
... 2010) The New York Stem Cell Foundation (NYSCF) today ... postdoctoral scientists join 15 accomplished stem cell researchers from leading ... NYSCF has awarded 23 fellowships to date. ... most competitive postdoctoral fellowship programs in the world, has so ...
... year The International Institute for Species Exploration at Arizona State ... previous calendar year. The list for 2009 was published to ... birth of Carl Linnaeus. It contains only two new plant ... Botanical Journal of the Linnean Society . ...
... SPRING HARBOR, N.Y. (Tues., June 1, 2010) -- ... frequently used techniques in RNA analysis. Electrophoresis is ... quality assessment. Gels are involved in a wide ... and analyzing processing reactions. The two most common ...
Cached Biology News:NYSCF awards fellowships to 8 innovative stem cell scientists 2NYSCF awards fellowships to 8 innovative stem cell scientists 3Rare carnivorous plant on top 10 list of newly discovered species 2Electrophoresis of RNA, avian imaging featured in June's Cold Spring Harbor Protocols 2
Alkaline Phosphatase (E. coli C75), 100 units. Removes 5'-phosphates from DNA. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzymes, Alkaline Phosphatases....
... Post-Labeling Reactive Dye Pack, 12 x ... specifically optimized for microarray labeling.Higher reactivity ... reactive dye per vial, at > ... individually dispensed, and packed in foil ...
... Quality ISO 9001:2000 Certified USDA ... Precedures Validated, SOP's Training AALAS ... for All Procedures GLP Documentation Upon Request ... stop shopping point for all your custom ...
UV-NIR light source for USB2000, HR4000, HR2000+...
Biology Products: